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Malignant melanoma of the anorectum is a rare disorder. Patients often present with local symptoms similar to benign 
diseases. The prognosis is very poor, and almost all patients die because of metastases. We report 2 female patients with 
unremarkable histories. Both of them received previous operations before visiting our center after they were diagnosed 
with anorectal malignant melanoma. One case underwent abdominoperineal resection and postoperative chemotherapy. 
The other had been treated with ultralow anterior resection followed by immunotherapy.
Keywords: Melanoma; Anorectal; Abdominoperineal resection; Ultralow anterior resection; Wide local resection
INTRODUCTION
Melanoma is a malignant disease that develops from the pigment-
containing cells known as melanocytes. This cancer commonly 
occurs in the skin, and its location at presentation differs between 
males and females. In women, melanoma most commonly occurs 
on the legs, while in men it is most common on the back [1]. His-
torically, melanoma of the anorectum is extremely rare, with a rel-
ative incidence of 0.5% to 4% of all malignancies in this region. 
The overall prognosis of anorectal melanoma is dismal, with a 10- 
to 19-month survival after diagnosis [2]. Many retrospective stud-
ies have confirmed the poor prognosis of anorectal melanoma. In 
2004, Malik et al. [3] reported a review of 19 patient records over 
the past 20 years who underwent operations, with a 5-year sur-
vival rate of about 21%. Similar to a retrospective study by Zhang 
et al. [4], another study reported that the 1-, 2-, 3-, and 5-year sur-
vival rates of anorectal patients were 58%, 33%, 24%, and 16%, re-
spectively, and the median survival time was 14.0 months.
Unfortunately, the management and treatment of anorectal mel-
anoma continue to be challenging for all physicians and surgeons. 
Until now, a feasible strategy was not available, and existing strate-
gies have not been consistent over time because of the lack of ran-
domized clinical trials and the rarity of this condition. Operative 
management has been considered an effective approach although 
controversy still exists regarding the benefit of radiation therapy 
and chemotherapy. The purpose of this article is to report 2 cases 
of anorectal melanoma and to discuss diagnostic and surgical 
treatment options.
CASE REPORTS
Written informed consent was obtained for publication of this 
case report and accompanying images.
Patient 1
A 52-year-old female presented to a local general hospital with 
the chief complaint of tenesmus and continuous rectal bleeding of 
several months duration. She reported no history of cutaneous 
melanoma and denied hypertension and diabetes mellitus. A 
perianal visual and digital examination showed a bleeding pedun-
culated mass sticking out from the anus and a huge hemorrhoid 
at 6 o’clock. A complete excision of the anal mass and hemor-
rhoidectomy were performed. The microscopic evaluation of the 
excised anal mass showed evidence of malignant melanoma with 
positive stains in immunohistochemistry for Human Melanoma 
Black 45 (HMB-45) and melan-A. The experts at the local hospi-
tal did not have much experience with anorectal melanoma, so 
the patient was transferred to our hospital.   
Colonoscopy, computed tomography (CT) of the thorax-abdo-
men, and magnetic resonance imaging (MRI) of the pelvis were 
performed for the purpose of staging the disease. The colonos-
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copy revealed a small ulcerated area (8 mm in diameter) 1.5 cm 
from the anal verge. CT of the thorax-abdomen demonstrated no 
evidence of lymph nodes or distant metastases. MRI confirmed a 
well preserved anorectal fat plane and several small regional 
lymph nodes at the perirectal space (Fig. 1).
The patient was diagnosed with anal melanoma, and her case 
was discussed at a multidisciplinary meeting. Due to the high sus-
picion of regional lymph nodes metastasis and the extended 
length of time from the onset of initial symptoms, an abdomino-
perineal resection (APR) was performed. She underwent laparo-
scopic-assisted APR along with left-side end colostomy and toler-
ated the surgical procedure without any complications. Evaluation 
of the pathologic specimen confirmed no evidence of a malignant 
lesion located in the anorectal wall. One of 4 regional lymph 
nodes was found to be positive for metastasis. Subsequently, she 
received adjuvant chemotherapy with a combination of cisplatin, 
vinblastine, and dacarbazine. At the 6-month follow-up visit, no 
evidence of metastasis was observed. 
Patient 2
A 39-year-old female with an unremarkable history underwent 
transanal excision of a polyp of the anal canal. The specimen con-
sisted of a polypoid mass measuring 2.5× 2.3 cm. The histopatho-
logical examination showed malignant melanoma and a clear re-
section, and the HMB-45 immunohistochemical stain result was 
positive. She visited our hospital for consultation about possible 
remnant tumor and the risk of recurrence. Therefore, we per-
formed a series of tests to identify the stage of the disease.
Colonoscopy confirmed no evidence of residual tumor, and there 
was a previous operative scar at the dentate line. Five biopsies 
were performed, all of which were negative for anorectal carci-
noma. MRI of the rectum showed 2 residual lymph node metas-
tases in the left lateral pelvic sidewall along the internal iliac axis 
and 2 other lymph node metastases in the left obturator and lat-
eral sacral area. No demonstrable residual primary lesions were 
seen in the rectum. Positron emission tomography (PET)/CT 
showed a focal fluorodeoxyglucose (FDG) uptake in the anal ca-
nal, which was attributed to postexcisional inflammatory change, 
and 2 round nodular lesions in the left perirectal area and left pre-
sacral pelvic with no discernible FDG uptake.
After consultation at a multidisciplinary team meeting, we de-
cided that she would undergo laparoscopic ultralow anterior re-
section (ULAR) with coloanal anastomosis and diversion ileos-
tomy, and she had an uncomplicated recovery. Gross examination 
showed a small scar located at the dentate line which corre-
sponded to the lesion from the first transanal operation. The his-
topathological report showed no residual malignant melanoma 
and metastatic malignant melanoma in 1 out of 42 regional lymph 
nodes in the following location; left internal iliac (0 of 5), inferior 
mesenteric artery (0 of 4), left common iliac (0 of 9), left obturator 
(1 of 9) and regional (0 of 15). The proximal and distal margins 
were free from tumor. She received immunotherapy (high-dose 
interferon [IFN]), and 13 months after the primary operation, she 
underwent ileostomy repair at which time there was no evidence 
of recurrence.
Sixteen months after the ULAR operation, a CT of the abdo-
men-pelvis demonstrated metastatic lymph nodes in the aortoca-
val space, and radiotherapy was initiated due to the evidence of 
recurrence (Fig. 2).
DISCUSSION
According to the United States National Cancer Database, the 
skin is the most prevalent site of melanoma, although it can occur 
in the mouth, intestine, or eye. Mucosal melanoma is rare and ac-
counts for approximately 1% of all melanomas. Mucosal melano-
mas occur mostly in the head and neck (55%), anorectum (24%), 
and vulvovaginal regions (18%) [5]. Anorectal mucosal mela-
Fig. 1. Case 1. (A) Preoperative magnetic resonance imaging confirmed a well preserved anorectal fat plane and small regional lymph nodes at 
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noma accounts for 0.05% of all colorectal malignancies and 1% of 
all anal canal cancers [6]. The median age at diagnosis of anorec-
tal melanoma is approximately 70 years old [7]. A study in Swe-
den concluded that the age-standardized incidence of anorectal 
melanoma was significantly higher for females (1.0 per 1,000,000 
females) than for males (0.7 per 1,000,000 males) throughout the 
40-year period [8]. Although several risk factors can increase the 
likelihood of skin melanoma, the risk factors for anorectal mela-
noma are not known. Epidemiologic data suggest that there is an 
increased risk associated with human immunodeficiency virus 
infection, so perhaps there is an association between anorectal 
melanoma and immunosuppression [6, 9].
The predominant local symptoms of anorectal melanoma are 
rectal bleeding, changed defecation pattern, and anorectal pain 
because 65% of anorectal melanomas are located within the anal 
canal or at the anal verge [6]. Unfortunately, most patients with 
anorectal melanoma are asymptomatic at the beginning of the 
disease, and if symptoms are present, they are similar to the clini-
cal presentation of benign anorectal diseases. This similarity can 
cause confusion and delayed diagnosis. The first step to diagnosis 
is biopsy through colonoscopy or proctoscopy. However, only 
34% to 41% of cases are correctly diagnosed before surgery [4, 
10]. Many patients are often misdiagnosed with a benign disease, 
and some cases are incidental findings at pathological analysis of 
tissue posthemorrhoidectomy [11], adenocarcinoma, or rectal ul-
cer [4]. Most lesions are polypoid, with or without pigmentation, 
and they can be ulcerated as well [12]. One-third of anorectal 
melanomas are amelanotic, and given their considerable morpho-
logic variability, misdiagnosis as lymphoma, carcinoma, or sar-
coma is common [13]. 
Immunohistochemical staining plays an important role in the 
diagnosis of anorectal malignant melanoma, and S-100 proteins, 
melan-A, HMB-45, and tyrosinase are commonly utilized. The 2 
most common melanocyte-specific stains for diagnosing malig-
nant melanoma are antibodies to melan-A and HMB-45. These 
antibodies are found almost only in cells that display some form 
of melanocytic differentiation, because the antibodies are distinc-
tive for premelanosome inner membrane proteins. Although 
these stains are very specific for melanocytic neoplasms, they 
have been found in other tumors with melanocytic differentia-
Fig. 2. Case 2. (A) Initial proctoscopy showed an anal mass. (B) Posttransanal excision colonoscopy confirmed no evidence of residual tumor. 
(C) Preoperative magnetic resonance imaging showed 2 residual lymph node metastases in the lateral pelvic sidewall along the internal iliac 
axis. (D) Postoperative pathological findings revealed that immunohistochemical staining for melanoma was positive with HMB-45 (×100). 
(E) Positron emission tomography/computed tomography 16 months after ultralow anterior resection demonstrated metastatic lymph nodes 
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tion, such as clear cell myomelanocytic tumors, lymphangioleio-
myomatosis, and angiomyolipomas [12].
Imaging diagnostic studies are used for malignant diseases of 
the anorectum, in particular, rectal adenocarcinoma. CT scan-
ning and ultrasonography are now important tools for staging 
and follow-up. In fact, endoscopy with biopsy is the best method 
for evaluating anorectal melanoma lesions. One study reported 
that CT scanning was used to diagnose primary rectal melanoma 
in 8 patients, and the primary rectal melanomas presented as 
bulky, intraluminal, fungating masses in the distal rectum focally 
expanding and obscuring the lumen without causing obstruction 
with perirectal infiltration and frequently enlarged lymph nodes 
[14]. Thus, CT scanning has the potential to be a useful tool in the 
assessment of regional diseases, especially if additional treatment 
methods such as chemotherapy or radiation therapy are also con-
sidered. PET can be used for staging cutaneous melanoma and 
may also be useful for staging anorectal melanoma. Its sensitivity 
was between 74% and 100% and specificity 67% in published re-
search [15]. 
Neither of the patients in the present report was correctly diag-
nosed in the beginning. Their first diagnoses were hemorrhoid 
and anal mass, leading to operative procedures in the previous 
hospitals. After the correct diagnosis had been established, each 
patient underwent a radical surgery because the disease was in 
the advanced stage with a large lesion and evidence of lymph 
node metastasis on pelvic MRI. Because of the short follow-up 
period, only short-term results could be assessed. The patient 
who received the APR procedure had no complications from sur-
gery, whereas the patient who received the ULAR experienced 
low anterior resection syndrome. She had severe diarrhea 10 
times per day for 6 months after the diverting ileostomy repair 
operation. This complication decreased over time. Regrettably, 16 
months after the radical operation, we discovered evidence of re-
currence (periaortic lymph nodes).
Generally, surgical excision is considered as a primary treatment 
option for anorectal melanoma. However, standard operative pro-
cedures related to the area of resection and lymphatic dissection 
have not been established. There has long been a debate in the lit-
erature regarding the extent of resection necessary to optimally 
treat anorectal melanoma. Because the disease is so rare, random-
ized control trials on appropriate management are lacking, and 
the existing evidence is primarily a result of retrospective studies. 
The standard operation for anorectal melanoma is considered to 
be APR because it can control lymphatic spread and ensure safe 
resection margins for local control. Together with the advantages 
of APR, this technique is among the most sophisticated proce-
dures. On the other hand, wide local excision (WLE) has clear ad-
vantages, including faster recovery, less invasive procedure, little 
impact on bowel function, and no need for a permanent stoma. 
However, it is true that the ULAR with total mesorectal clearance 
has been shown to be one of the most crucial approaches in treat-
ing low rectal cancer, but using ULAR for anorectal melanoma 
has never been reported. In theory, ULAR has the advantage of a 
wider excision than WLE and is equal with APR. Additionally, 
mesenteric lymphadenectomy could be adequately conducted by 
ULAR. A stellar advantage of ULAR compared to APR is preserv-
ing the gastrointestinal continuity. 
An early study reported by Brady et al. [2] in 1995 suggested 
that aggressive treatment of the primary anorectal lesion with 
APR was associated with improved outcome, possibly due to re-
gional lymphadenectomy. Among the 71 patients with resectable 
disease, the 5-year disease-free survival distribution of patients 
who underwent APR was more favorable than group who re-
ceived local procedures only, although this was not statistically 
significant (27% vs. 5%, respectively; P= 0.11). However, those 
who had APR were more likely to survive long term than those 
who did not (P< 0.05) [2]. 
Yeh et al. [16] concluded in their study that there has been a 
gradually dramatic shift in surgical treatment toward less radical 
procedures. Prior to 1997, the majority of patients (15 of 21, 71%) 
underwent APR. After 1997, the majority of patients (21 of 25, 
84%) underwent local excision. There was no significant differ-
ence in local recurrence between patients who underwent APR 
vs. local excision, and the 5-year specific survival was similar [16]. 
A study of 251 patients with anorectal melanoma from 1960 to 
1999 from the Swedish National Cancer Registry was conducted 
by Nilsson and Ragnarsson-Olding [17]. Sixty-six patients under-
went APR, and 86 patients underwent local excision. The median 
survival among the patients who were treated with either APR or 
local excision was 14 months, and there was no statistically signif-
icant difference in median survival rate. The overall 5-year sur-
vival rate was 11.2% [15, 17].
Lymph node dissection may be indicated in clinically apparent 
disease or for occult disease identified with a sentinel lymph node 
(SLN). SLN dissection has largely been accepted as the standard 
of care for intermediate thickness cutaneous melanoma [18]. Ex-
perience with cutaneous melanoma has revealed a survival bene-
fit if lymph node dissection is performed. SLN dissection has also 
been used with anorectal melanoma. A few case reports exist re-
garding the technical feasibility of sentinel node biopsy with ano-
rectal melanoma, but the efficacy remains unknown [19]. Sentinel 
node biopsy may detect clinically unapparent groin adenopathy, 
and the subsequent inguinal dissection may provide a curative re-
section for a small subset of patients. It is technically feasible, but 
the numbers are too small to draw any meaningful conclusions at 
this time. 
Unfortunately, there is still no guideline for systemic therapy for 
melanoma. Many studies consider chemotherapy and radiation 
therapy to be effective. Cisplatin, vinblastine, dacarbazine, IFN-α, 
and interleukin-2 are medications that may be prescribed for the 
treatment of this condition [20]. Another combination of chemo-
therapy known as the “Dartmouth regimen” uses dacarbazine, 
cisplatin, carmustine, and tamoxifen. A study of 240 patients 
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men increased the response rate. However, the increase was not 
statistically significant, and patients in both groups had a mean 
survival of 7 months [21]. Radiation therapy has almost no treat-
ment effect and is mainly used in palliative care for unresectable 
tumors.
Recently, we have come to understand the relationship between 
some checkpoint proteins on T cells and the growth of cancer 
cells, for instance, PD-1/PDL-1 and CTLA-4. Malignant cells 
could take advantage of checkpoint proteins to develop and hide 
from the immune system of the body so that T cells cannot kill 
them. Humanized monoclonal antibodies, such as ipilimumab 
(likely blocks CTLA-4) and nivolumab and pembrolizumab (po-
tentially block PD-1), on primed T cells have been accepted and 
used as standard therapies for malignant melanoma. Studies show 
that the response rate to inhibitor therapy is between 30% and 
50% of patients, which is superior to chemotherapy [22]. How-
ever, this therapy is not applicable to all patients. Furthermore, it 
may lead to serious immune-related adverse events. The use of 
this therapy is still a challenge in some developing countries, be-
cause the cost is too high and it isn’t paid for by health insurers.
In conclusion, anorectal melanoma is a rare malignant disease 
with a poor prognosis. Patients could be misdiagnosed as having 
hemorrhoids or a polyp due to the nonspecific symptoms of anal 
pain, rectal bleeding, or a small mass at the anorectum. Immuno-
histochemical staining for proteins, such as HMB-45, melan-A, 
and S-100, is very useful for the definite diagnosis of anorectal 
melanoma. Surgical resection still remains the cornerstone and 
most important treatment in the management of anorectal mela-
noma. Two surgical approaches are favored; APR and wide local 
resection. Until now, there have been no complete trials that dem-
onstrated APR or WLE provide superior long-term survival.
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